Increased action of triclabendazole (TCBZ) in vitro against a TCBZ-resistant isolate of Fasciola hepatica following its co-incubation with the P-glycoprotein inhibitor, R(+)-verapamil.

@article{Savage2013IncreasedAO,
  title={Increased action of triclabendazole (TCBZ) in vitro against a TCBZ-resistant isolate of Fasciola hepatica following its co-incubation with the P-glycoprotein inhibitor, R(+)-verapamil.},
  author={Jason Savage and Myles Meaney and Gerard P. Brennan and Elizabeth M. Hoey and A. G. Trudgett and Ian Fairweather},
  journal={Experimental parasitology},
  year={2013},
  volume={135 3},
  pages={642-53}
}
A study has been carried out to investigate whether the action of triclabendazole (TCBZ) against Fasciola hepatica is altered by inhibition of P-glycoprotein (Pgp)-linked drug efflux pumps. The Sligo TCBZ-resistant fluke isolate was used for these experiments and the Pgp inhibitor selected was R(+)-verapamil [R(+)-VPL]. In the first experiment, flukes were… CONTINUE READING